Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELA-101 in Healthy Adults and Participants with Hyperlipidemia
NCT07864311Phase 1Not yet recruiting
- Sponsor
- Ursa Medicines
- Start
- Nov 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VELA-101 in hyperlipidemia (4 arms), sponsored by Ursa Medicines. Primary endpoint: Incidence and severity of treatment-emergent adverse events and vital signs, electrocardiogram, and clinical laboratory parameters at Day 180. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
VELA-101
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT07864311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07864311.